<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557541</url>
  </required_header>
  <id_info>
    <org_study_id>2013/8863</org_study_id>
    <nct_id>NCT03557541</nct_id>
  </id_info>
  <brief_title>Sardine-enriched Diet for Prevention Type 2 Diabetes</brief_title>
  <official_title>Sardine-enriched Diet for Prevention Type 2 Diabetes in Elderly and Prediabetic Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut d'Investigacions Biomèdiques August Pi i Sunyer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis formulated is that 200 g of sardine on a weekly basis will have a favourable
      impact avoiding the natural development of the pathology due to changes in the biochemical
      profile, the anthropometrics, inflammatory markers, changes in gut microbiota populations,
      also in transcriptomics and metabolomics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>type 2 diabetes new onset</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>incidence of new diagnosis of type 2 diabetes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adiponectin</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>adiponectin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantification of gut microbiota populations</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>quantification by q-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>relative expression related genes by RT q-PCR (Real Time Quantitative Reverse transcription polymerase chain reaction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolomics study of dietary biomarkers and health biomarkers [(1) Fatty acyls, bile acids, steroids and lysoglycerophospholipids, (2) Glycerolipids, glycerophospholipids, sterol lipids and sphingolipids, (3) Amino acids.]</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>endogenous metabolic profiles of serum samples will be studied using ultra-high performance liquid chromatography - mass spectrometry (UHPLC-MS). The same unit for measurements [log2 (fold change)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose homeostasis</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>glucose (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin levels</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>insulin (mU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR (homeostasis model assessment insulin resistance)</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>insulin resistance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-B (homeostasis model assessment B cell function)</measure>
    <time_frame>Change from Baseline at 12 months</time_frame>
    <description>B cella function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>PreDiabetes</condition>
  <condition>Diet Habit</condition>
  <condition>Diabetes</condition>
  <condition>Nutritional and Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Sardine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sardine</intervention_name>
    <description>They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)</description>
    <arm_group_label>Sardine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>They received a common T2D-preventive diet</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  glycaemia between 100-125 md / dL or ≥5.7% HbA1c

        Exclusion Criteria:

          -  treatment with oral antidiabetic drugs

          -  any nutritional education to prevent T2D

          -  Suspect or known hypersensitivity to sardine or related fish

          -  Chronic treatment with oral steroids and / or AINES

          -  Treatment with oral antidiabetic agents and / or insulin

          -  Treatment with immunosuppressive drugs

          -  Diagnosis of active neoplasm

          -  Diagnosis of HIV or AIDS

          -  Abnormal liver profile (&gt; 6 times normal values)

          -  Diagnosis of Acute Psychiatric Sdr

          -  Presence of serious acute concomitant disease, which it requires more than 7 days of
             recovery.

          -  Major cardiovascular event (stroke, myocardial infarction) in the month prior to
             randomization.

          -  Any other condition that the investigator considers to be inoperative so that the
             subject conducts the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diana A Diaz Rizzolo</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigacions Biomèdiques August Pi i Sunyer</investigator_affiliation>
    <investigator_full_name>Diana Alicia Diaz Rizzolo</investigator_full_name>
    <investigator_title>RD, Msc, PhD candidate</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>T2D</keyword>
  <keyword>diet</keyword>
  <keyword>nutrition</keyword>
  <keyword>prediabetes</keyword>
  <keyword>sardine</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 28, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03557541/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03557541/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

